      Document 0010
 DOCN  DRG0010
 UNIQUE IDENTIFIER        DRG-0237
 NAME OF SUBSTANCE        Selegiline hydrochloride [USAN 1996]
 REGISTRY NUMBER          14611-52-0
 STANDARD CHEMICAL NAME   Benzeneethanamine, N,
                          alpha-dimethyl-N-2-propynyl-, hydrochloride,
                          (R)- [USAN 1996]
 SYNONYMS                 Eldepryl [USAN 1996]
 SYNONYMS                 Deprenyl [FDA 250A]
 PROTOCOL ID NUMBERS      FDA 250A
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: Irreversibly inhibits
                          monoamine oxidase (MAO), an intracellular
                          enzyme associated with the outer membrane of
                          mitochondria, by acting as a suicide
                          substrate for the enzyme, i.e., it is
                          converted by MAO to an active moiety that
                          combines irreversibly with the active site
                          and/or the enzyme's essential FAD cofactor.
                          [PDR 1995]
 DISEASES STUDIED/TREATED HIV-associated dementia [FDA 250A]
 CLASSIFICATION CODE      Monoamine oxidase inhibitor [PDR 1995]
 CLASSIFICATION CODE      Antidyskinetic [USAN 1996]
 CLASSIFICATION CODE      Antiparkinsonian [USAN 1996]
 OTHER MAJOR USES         Management of Parkinson's disease in patients
                          who experience deterioration on
                          levodopa/carbidopa therapy. [PDR 1995]
 SUBSTANCE INTERACTIONS   Interacts with meperidine. [PDR 1995]
 ADVERSE EFFECTS          Adverse effects may include nausea,
                          hallucinations, confusion, depression, loss
                          of balance, isomnia, orthostatic hypotension,
                          increased akinetic involuntary movements,
                          agitation, arrhythmia, bradykinesia, chorea,
                          delusion, hypertension, new or increased
                          angina pectoris and syncope, headache, leg
                          pain, back pain, tinnitus, migraine,
                          supraorbital pain, burning throat, chills ,
                          numbness in fingers and toes, taste
                          disturbance, constipation, weight loss,
                          anorexia, dysphagia, diarrhea, rectal
                          bleeding, slow urination, urinary frequency,
                          increased sweating, diaphoresis, facial hair,
                          hair loss, hematoma, rash, and
                          photosensitivity. [PDR 1995]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Levorotatory acetylenic
                          derivative of phenethylamine [PDR 1995]
 CHEMICAL/PHYSICAL DATA   MOLECULAR FORMULA: C13H17N.HCl [USAN 1996]
 CHEMICAL/PHYSICAL DATA   MOLECULAR WEIGHT: 223.75 [USAN 1996]
 CHEMICAL/PHYSICAL DATA   SOLUBILITY: Freely soluble in water,
                          chloroform, and methanol [PDR 1995]
 CHEMICAL/PHYSICAL DATA   PHYSICAL DESCRIPTION: White to near white
                          crystalline powder [PDR 1995]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: 5 mg tablets. [PDR 1995]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Oral. [PDR 1995]
 SUBSTANCE DELIVERY DATA  STORAGE INSTRUCTIONS: Store at 15-30 C. [PDR
                          1995]
 MANUFACTURERS            Somerset Pharmaceuticals Inc
 ENTRY MONTH              9511
 LAST REVISION DATE       951129
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
